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Abstract
Background: Thymic epithelial tumours (thymoma and carcinoma) are exceptionally rare in children. We describe
a national multicentre series with a view to illustrating their clinical behaviour and the results of treatment.
Methods: From January 2000 all patients under 18 years of age diagnosed with “rare paediatric tumours“ were
centrally registered by the Italian centres participating in the TREP project (Tumori Rari in Età Pediatrica [Rare
Tumours in Paediatric Age]). The clinical data of children with a thymic epithelial tumour registered as at
December 2009 were analyzed for the purposes of the present study.
Results: Our series comprised 4 patients with thymoma and 5 with carcinoma (4 males, 5 females; median age
12.4 years). The tumour masses were mainly large, exceeding 5 cm in largest diameter. Based on the Masaoka
staging system, 3 patients were stage I, 1 was stage III, 1 was stage IVa and 4 were stage IVb.
All 3 patients with stage I thymoma underwent complete tumour resection at diagnosis and were alive 22, 35 and
93 months after surgery. One patient with a thymoma metastasizing to the kidneys died rapidly due to respiratory
failure.
Thymic carcinomas were much more aggressive, infiltrating nearby organs (in 4 cases) and regional nodes (in 5),
and spreading to the bone (in 3) and liver (in 1). All patients received multidrug chemotherapy (platinum
derivatives + etoposide or other drugs) with evidence of tumour reduction in 3 cases. Two patients underwent
partial tumour resection (after chemo-radiotherapy in one case) and 4 patients were given radiotherapy (45-54 Gy).
All patients died of their disease.
Conclusions: Children with thymomas completely resected at diagnosis have an excellent prognosis while thymic
carcinomas behave aggressively and carry a poor prognosis despite multimodal treatment.
Background
Primary thymic epithelial neoplasms, thymomas and
thymic carcinomas, are uncommon tumours with an
annual incidence of approximately 1-5 per million popu-
lation [1]. Their aetiology is still largely unknown, but
thymoma has been reported in association with multiple
endocrine neoplasia syndrome type 1 (MEN1) and auto-
immune disorders [2].
Thymoma is classified in two main types, depending
on whether the neoplastic epithelial cells and their
nuclei are uniformly bland (type A thymoma) or have a
predominantly round or polygonal appearance (type B)
[3]. Type B thymomas are further divided into three
subtypes according to the extent of lymphocytic infil-
trate and the degree of atypia of the neoplastic epithelial
cells, i.e. B1 (richest in lymphocytes), B2, and B3 (richest
in epithelial cells). Thymomas combining type A with
B1-like or (rarely) B2-like features are designated type
AB.
Thymic carcinomas are termed according to their dif-
ferentiation (squamous cell, muco-epidermoid, etc.) [1].
In adults, the main histological subtypes in most pub-
lished series are type B2 and AB thymomas (with 20-
35% of all cases each) [4]. The percentage of thymic car-
cinomas is reportedly about 10-25% [5].
These tumours show variable clinical behaviour ran-
ging from a tendency to be indolent and non-invasive to
highly infiltrative tumours with metastatic spread to the
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[6].
Thymic tumours are exceptionally rare in the paedia-
tric age group, accounting for less than 1% of childhood
mediastinal tumours [7]. As in adults, thymic tumours
in children may be asymptomatic or present with com-
pressive symptoms. They are classified and staged in the
same way as adult tumours but there are very few
reports on the treatment of thymic tumours in children.
With a view to promoting research on, and improving
the clinical management of very rare paediatric cancers
(childhood solid malignancies characterised by an
annual incidence <2/million and not considered in other
clinical trials) a nationwide cooperative initiative called
t h eT R E Pp r o j e c t( T u m o r iR a r ii nE t àP e d i a t r i c a[ Rare
Tumours in Paediatric Age]) was launched in Italy in
2000 [8,9]. Thymic tumours were included in this pro-
ject and here we describe the clinical features, treatment
and outcome of the TREP series patients with this
diagnosis.
Methods
All patients under 18 years of age with a diagnosis of
“rare paediatric tumours“ were centrally registered from
1 January 2000 onwards by all the Italian centres partici-
pating in the TREP project. The present study focuses
on the clinical data recorded for 9 children with a histo-
logically confirmed diagnosis of epithelial tumour of the
thymus treated between January 2000 and December
2009. The series included 4 males and 5 females, with a
median age of 12.4 years (range 4.8 - 16.3 years).
TREP diagnostic and therapeutic recommendations
Guidelines were developed to help paediatric oncologists
diagnose thymic tumours. After chest X-ray, computed
tomography (CT) and/or magnetic resonance imaging
(MRI) were recommended to assess local tumour extent.
A bone marrow biopsy was part of the diagnostic work-
up to rule out lymphatic neoplasms. Surgical guidelines
suggested that primary excision should be attempted via
a sternotomy if non-mutilating, and complete resection
was considered feasible; if not, a biopsy was to be taken
for diagnostic purposes. The criteria adopted for diagnos-
ing thymoma or thymic carcinoma were as stated by the
WHO classification. Tumours were staged according to
the commonly-used Masaoka staging system [10]
(Table 1). The distinction between tymoma and thymic
carcinoma was based on the local pathology report. In
addition 5 cases were reviewed by the TREP Pathology
Panel and no discrepancies with the local diagnosis were
noted.
The paucity of data in the literature prevented us from
establishing a strict protocol, but radiotherapy and che-
motherapy were recommended in an attempt to reduce
the tumour mass and make delayed surgery feasible.
The guidelines stated that the most often used multi-
drug regimens included cisplatin, doxorubicin, vincris-
tine and cyclophosphamide.
Results
Patients
The patients’ demographic data are shown in Table 2.
Eight children in our series were symptomatic, pain
being the most frequent symptom (in 5 patients). Com-
pression of the respiratory tract by the mediastinal
tumour caused chronic coughing in 2 patients and dys-
pnoea in 2 (with airway compression and coma in 1).
General symptoms (fatigue, fever, weight loss) were
observed in 5 patients. One child had 2 paraneoplastic
autoimmune syndromes (systemic lupus erythematosus
and hypertrophic pulmonary osteoarthropathy). In one
asymptomatic child, the tumour was diagnosed inciden-
tally, after a radiological assessment for scoliosis.
The tumour masses were generally large at diagnosis,
exceeding 5 cm in largest diameter in 7 cases (and more
than 10 cm in 4 of them).
The thymic carcinomas revealed a very aggressive
behaviour with infiltration of adjacent organs (in 4
cases), regional lymph node invasion (in 5) and metas-
tases to the bone (in 3) and liver (in 1). One child with
thymoma had distant metastases to both kidneys.
According to the Masaoka staging system, 3 patients
were classified as stage I, 1 as stage III, 1 as stage IVa
and 4 as stage IVb.
Treatment
A complete primary resection was performed at diagno-
sis in 3 patients with stage I thymoma, involving a ster-
notomy in 2 cases and a left thoracotomy in one.
In one child, the histopathological diagnosis of thy-
moma was established on autopsy after a rapid death
due to respiratory failure resulting from compression of
the respiratory tract by an unrecognized mediastinal
tumour.
Among the 5 patients with carcinoma, a tumour resec-
tion was attempted in two (after chemo-radiotherapy in
one), but left macroscopic residual disease; a biopsy of the
enlarged regional lymph nodes was performed for
Table 1 Thymoma staging according to Masaoka et al.
[10]
Stage I Totally encapsulated
Stage II Capsular invasion and/or invasion into surrounding fat or
pleura
Stage III Invasion into organs (pericardium, lung, great vessels)
Stage IV-A Pleural or pericardial implants
Stage IV-B Haematogenous metastases
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motherapy based on platinum derivatives in association
with etoposide (2 cases) or other drugs. A tumour volume
reduction was evident in three cases (see table: N 6, 8 and
9), ranging from 25% to 66%, but the response was short-
lived (1 to 3 months).
Radiotherapy to the mediastinal region was adminis-
tered in 4 patients, in doses ranging from 45 to 54 Gy.
Outcome
The disease progressed in all 5 patients with carcinoma,
who died from 7 to 17 months after its diagnosis. One
child with thymoma also died soon after being admitted
to hospital due to compression of the respiratory tract
by the tumour mass. The 3 patients with stage I thy-
moma were alive with no evidence of disease 22, 35 and
93 months after complete tumour excision.
Discussion
Our report confirms that thymic tumours are very
uncommon in the paediatric age group.
In adults, the clinical behaviour of thymic tumours
may vary from an indolent course to a very aggressive
one. The WHO classification describes subtypes with a
progressively worsening prognosis: thymoma types A,
A B ,a n dB 1h a v ear e l a t i v e l yg o o do u t c o m e ;B 2a n dB 3
are more aggressive and have intermediate survival
rates, while thymic carcinoma carries the worst prog-
nosis [3].
For thymomas, the WHO histological classification
and the Masaoka staging system are independent prog-
nostic factors. Based on the Masaoka staging system, the
20-year survival rates are reportedly 89%, 91%, 49%, 0%,
and 0% in patients with Stages I, II, III, IVa, and IVb
disease, respectively [11].
Table 2 Clinical characteristics and treatment
N Tumour type Age
(years)
Stage Symptoms Size
(cm)
Local
extent
Lymph
nodes
Metastasis Surgery CT RT
(Gy)
Outcome/
FU (m)
1 Thymoma B1 4.8 I Cough >5 e
<10
no no no Complete
resection at
diagnosis
No No 1°CR/35.2
2 Thymoma B1 12.4 IVb Dyspnoea,
coma
Kidney,
bilaterally
No No No Died
3 Thymoma B1 11.4 I Incidental
(radiography
for scoliosis)
4×2.5×2 no no no Complete
resection at
diagnosis
No No 1°CR/93.40
4 Thymoma AB 15 I Chest pain,
fever
16×8×14 no no no Complete
resection at
diagnosis
No No 1°CR/21.7
5 Lympho-
epithelioma-like
carcinoma
11.7 III Chest pain,
joint pain,
fever,
butterfly
rash, digital
clubbing
12×9×6 Lung,
lymph
node
Mediastinal no Incomplete
resection at
diagnosis
Ifo-VCR
+ACT (1
cycle)
CDDP
+VP16 (2
cycles)
50 Died/12
6 Carcinoma with
neuroendocrine
differentiation
15.5 IVb Shoulder
pain
10×6×12 Sternum,
pleural/
pericardial
effusion
Latero-
cervical,
mediastinal
Bone Lymph node
biopsy at
diagnosis
CDDP+
VP16 (7
cycles)
Yes Died/17
7 Poorly
differentiated
carcinoma
14.7 IVb Fever,
vomiting,
weight loss,
abdominal
and chest
pain
>5 Lung Mediastinal Bone Lymph node
biopsy at
diagnosis
CDDP+5FU
(1 cycle)
CDDP
+ADR+VCR
+CPM (5
cycles)
45 Died/10
8 Poorly
differentiated
carcinoma
16.3 IVb Cough, fever,
fatigue, back
pain
>5 e
<10
no Latero-
cervical
Liver, bone Lymph node
biopsy at
diagnosis
CDDP
+CPM
+ADR (4
cycle)
No Died/7
9 Lympho-
epithelioma-like
carcinoma
12 IVa Fatigue,
weight loss,
dyspnoea
10×10 Pleural
nodes and
effusion
Left hylar,
mediastinal
no Incomplete
resection after
chemotherapy
CDDP+5FU
(4 cycles)
CDDP (6
cycle)
54 Died/16
IFO = Ifosfamide, VCR = Vincristine, ACT = Actinomycin, CDDP = Cisplatin, VP16 = Etoposide, 5FU = Fluorouracil, CPM = Cyclophosphamide, ADR = Adriamycin,
CT = chemotherapy, RT = radiotherapy, FU = follow-up (months), 1°CR = first complete remission
Carretto et al. Orphanet Journal of Rare Diseases 2011, 6:28
http://www.ojrd.com/content/6/1/28
Page 3 of 5Surgical resection is the mainstay of treatment for
patients presenting with Masaoka Stage I or II disease;
complete tumour resection is accompanied by complete
thymectomy, the removal of all surrounding mediastinal
fat and possibly also the pleura, to increase the chances
of ensuring negative surgical margins [12].
Patients achieving a complete resection of a stage I
tumour have a 5-year survival rate of 100% and a recur-
rence rate of 1% [13]; these patients are not considered
candidates for adjuvant therapies.
Our limited experience suggests that thymomas in
children have a similar behaviour with stage I thymoma
having a favourable outcome. No further treatment was
necessary in our cases after tumour removal. Conversely,
the child with stage IV thymoma died of disease even
before any therapy could be attempted.
Published experiences of paediatric thymoma are lim-
ited, but report similar results: In agreement with our
results, Dhall [14] reported on 2 cases of thymoma
(Masaoka stage I) treated with complete resection: both
patients were still disease-free 3 years after surgery. Liang
[15] reported on 2 cases of thymoma and provided a
comprehensive review and analysis of paediatric cases
reported in the past 30 years (32 cases in all): among 17
patients with stage I and II tumours, 16/17 patients (94%)
were alive when their case was published (with a follow-
up ranging from 3 months to 9 years), whereas only 3 of
9 patients (33%) with stage IV disease survived.
In adults, thymic carcinomash a v eam o r ea g g r e s s i v ec l i n -
ical course than thymomas and they are associated with a
poor prognosis. They are frequently not amenable to radical
resection at diagnosis so multimodal therapies (including
neo-adjuvant or adjuvant chemo-radiotherapy) are
employed. Overall, the results obtained in adults with thy-
mic carcinoma are unsatisfactory, with a reported 5-year
survival rate of around 50% and a mean survival of 2.5
years [13,16 ,17]. Subgroup analysis has revealed a signifi-
cant difference in survival rates between patients achieving
total versus subtotal resections, and between totally resected
a n di n o p e r a b l eg r o u p s .T h es u r v i v a lr a t ea l s od i f f e r e ds i g n i f -
icantly between patients receiving radio-chemotherapy and
those receiving radiotherapy alone, and between the former
and those given no adjuvant therapy [13].
Igawa [18] conducted a retrospective study on the effi-
cacy and safety of combined CBDCA (carboplatin) +
paclitaxel therapy in 11 previously-untreated patients
with unresectable advanced thymic carcinomas: the
overall median survival time was 22.7 months and the
1-year survival rate was 62%.
Studies describing children with thymic carcinoma are
scarce. Yaris [19] reviewed the English literature and
described 15 cases under 18 years of age, most of whom
presented with an anterior mediastinal mass and suf-
fered from chest pain, cough, fever, weight loss, and
respiratory distress. Radiologically, these tumours were
often associated with pleural effusions and/or the invol-
vement of neighbouring structures such as the pleura
and pericardium. Nine patients died (8 of them with
metastatic disease) within 1.5 to 15 months of their
diagnosis, 4 were alive (2 of them without disease) from
1 to 12 years after their diagnosis.
A recent report from the Polish Rare Tumour group
[20] described 9 children with thymic carcinomas: 2
were classified as Masaoka stage II, 5 as stage III, and 2
as stage IV. Only 1 patient underwent complete tumour
resection at diagnosis, six received multidrug che-
motherapy and 4 had radiotherapy. The outcome was
dismal, and only 2 children were long-term survivors.
The cases of thymic carcinoma in our series all had
unfavourable features: they all presented with large masses
and evidence of local or distant spread. Only a diagnostic
biopsy was performed in 3 patients and an attempt at
tumour resection in 2 left macroscopic residuals. Despite
the administration of chemotherapy and radiotherapy,
these tumours remained unresectable and all patients died.
Four patients in our series received radiotherapy, but
it failed to reduce the tumour bulk. In the series pub-
lished by the Polish group, 4 children were irradiated
and 2 of them (with stage II and stage III disease) were
still alive, though one of them unfortunately developed
severe neurological sequelae due to radiation-induced
spinal damage.
Although thymic tumours seem to be sensitive to che-
motherapy, the most effective regimen remains to be
established. Different drug combinations have been
used, generally based on cisplatin, doxorubicin, cyclo-
phosphamide and prednisone [21].
In our experience, we only found evidence of a short-
lived tumour response in 3 children treated with cisplatin
based chemotherapy. Similar results were obtained by the
Polish group, with 4 out of 5 assessable children showing
a tumour response after initial chemotherapy. Different
regimens were administered, however, making it hard to
say which is the most effective combination [20].
More effective drugs are therefore needed and tar-
geted molecular therapies might pave the way to new
therapeutic options in patients with thymic carcinoma
in advanced stages. Strobel et al. [22] described the first
case of a carcinoma with an activating KIT mutation
and suggested that screening for activating KIT muta-
tions may identify KIT-expressing carcinomas that could
benefit from imatinib. The same authors [23] described
4 patients of metastatic thymic carcinoma refractory to
conventional therapies who were treated with sunitinib,
a multi-targeted tyrosine kinase inhibitor; 2 patients
were still in partial remission after 14 and 18 months on
sunitinib, one patient died 4 months after starting suni-
tinib, and the last patient was alive with stable primary
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sion of coeliac lymph node metastases.
Conclusions
Thymic tumours are very rare in the paediatric age group.
Like their adult counterparts, children with thymomas
that are completely resected at diagnosis have an excellent
prognosis. Thymic carcinomas behave very aggressively,
however, and the prognosis is poor. The TREP project has
demonstrated that cooperative studies are feasible even on
exceptionally rare tumours and this approach should be
transferred to a more international level in an effort to
establish the best treatment for these very rare tumours.
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